CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM Jul 01, 2021 9:05am EDT
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme Jun 29, 2021 8:35am EDT
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin May 19, 2021 8:05am EDT
CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook May 14, 2021 9:05am EDT
CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference Mar 15, 2021 9:00am EDT
CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference Mar 04, 2021 9:00am EST
WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study Feb 18, 2021 9:05am EST
